GSK is focused on the research and development of medicines for immune-mediated diseases, such as lupus and rheumatoid arthritis, that are responsible for a significant health burden to patients and society. Our world-leading scientists are focusing research on the biology of the immune system with the aim to develop immunological-based medicines that have the potential to alter the course of inflammatory disease. As the only company with a biological treatment approved for adult lupus, GSK is leading the way to help patients and their families manage this chronic, inflammatory autoimmune disease. Our aim is to develop transformational medicines that can alter the course of inflammatory disease to help people live their best day, every day.
Throughout our history as an innovator in autoimmune diagnostics, we’ve been driven by a simple mission: help labs improve the way patients with autoimmune diseases are diagnosed, monitored, and treated. Inova Diagnostics continually works with clinical researchers to develop new biomarkers for more accurate testing. We also collaborate with experts in automation to deliver more efficient systems that help clinical labs improve their testing processes. The Integrated Lab is comprised of a portfolio of instruments seamlessly connected to the LIS using QUANTA Link, a data management system. Integrated Lab instruments include the new AptivaTM* system for particle based multi-analyte testing (PMAT), BIO-FLASH® rapid-response chemiluminescent analyzer, QUANTA-Lyser® EIA/IFA processor, and NOVA View® digital IFA microscope. Come visit our booth or our website (www.inovadx.com) for more details.
* In development. Not for sale
† Not for sale in the US
UCB is a global biopharmaceutical company. Our ambition is to transform the lives of people living with severe diseases. We focus on neurology and immunology disorders – putting patients at the centre of our world. We are Inspired by Patients. Driven by Science.
IE-P-CZ-axSpA-1900039. Date of Preparation: May 2019
Endotelix is dedicated to providing fast, sensitive and reliable solutions for Antiphospholipid Syndrome including diagnostic tests and treatment options. We are currently developing a new diagnostic test to measure the circulating levels of antiphospholipid antibodies (aPL) as a rapid test (LFA). It allows the measuring of anti-β2GP1 IgG and IgM. This diagnostic test is more sensitive and faster than all current assays. We are also developing an ELISA test for hospital and Research Use Only
Professor Graham Hughes is working as an independent consultant and is not an employee of HCA International Limited. HCA does not accept responsibility for the contents of messages sent from this email address or any consequences that may arise from your reliance thereon.
The contents of this email are confidential and copyright may also be privileged. They are intended only for the use of the addressee(s) shown above. Any unauthorised reading, use, distribution or copying of them is prohibited. If this email has been sent to you in error, you may not take action based on it, nor may you rely on it for any purpose. Please let me know of the error by telephone and please return the email.
Whilst all reasonable care has been taken to avoid the transmission of viruses, it is the responsibility of the recipient to ensure that the onward transmission, opening or use of this message and any attachments will not adversely affect its systems or data. No responsibility is accepted by HCA International Limited in this regard and the recipient should carry out such virus and other checks as it considers appropriate.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our latest treatments.
Precision BioLogic develops, manufactures and markets hemostasis diagnostic products. Over the past several years, we have expanded beyond the clinical laboratory and applied our expertise to assist pharmaceutical companies in various stages of product development and deployment. With the recent acquisition of Affinity Biologicals, we’ve grown our offerings to include an extensive line of coagulation-related antibodies as well as other products and services. Together, we’re innovating to advance hemostasis-related diagnostics and research.
Thermo Scientific, a premier brand of Thermo Fisher Scientific, develops, manufactures, and markets complete blood test systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases. We are the global leader in ImmunoDiagnostics in vitro allergen sensitization testing and also the European leader in autoimmunity diagnostics. The allergy and autoimmunity product lines operate on a common automated instrument platform, Phadia Laboratory Systems, that supports laboratory productivity and efficiencies around the world.
Thrombosis UK is a leading UK charity working to raise awareness, extend understanding and support research into thrombosis (blood clots) often known as deep vein thrombosis (DVT) – blood clots most commonly in a limb, or pulmonary embolism (PE) – blood clots in the lungs. The charity works with patients, carers, relatives and bereaved as well as health care and allied professionals and all interested parties. From provision of a help line, information resources, educational conferences and support for research, our aim is to improve awareness and understanding of thrombosis in order to prevent avoidable events, improve early detection leading to early diagnosis and support implementation of best management of thrombosis to safeguard and improve patient outcomes. Thrombosis UK does not have a formal ‘membership’ but works freely with individuals. We currently have over five thousand active followers and supporters across patient, general public and health care professionals. To find out more please visit: www.thrombosisuk.org
Interested in Partnership & Exhibition Opportunities?
ICAPA 2019 is an excellent opportunity for you to engage with the clinical community (haematologists, rheumatologists, neurologists, research scientist’s, obstetricians and fetal and maternal medicine specialists, fertility specialists, immunologists, paediatricians, health policy makers and others working in the field). We expect over 350 healthcare professionals to join us at this three-day international congress in the vibrant city of Manchester.